Cargando…
Hyperprolactinemia due to pituitary metastasis: A case report
BACKGROUND: Pituitary metastasis is an uncommon manifestation of systemic malignant tumors. Moreover, hyperprolactinemia and overall hypopituitarism caused by metastatic spread leading to the initial symptoms are rare. CASE SUMMARY: A 53-year-old male patient was admitted to our hospital with compla...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7809681/ https://www.ncbi.nlm.nih.gov/pubmed/33511184 http://dx.doi.org/10.12998/wjcc.v9.i1.190 |
_version_ | 1783637166834843648 |
---|---|
author | Liu, Chun-Yang Wang, Yu-Bo Zhu, Hui-Qin You, Jin-Liang Liu, Zhuang Zhang, Xian-Feng |
author_facet | Liu, Chun-Yang Wang, Yu-Bo Zhu, Hui-Qin You, Jin-Liang Liu, Zhuang Zhang, Xian-Feng |
author_sort | Liu, Chun-Yang |
collection | PubMed |
description | BACKGROUND: Pituitary metastasis is an uncommon manifestation of systemic malignant tumors. Moreover, hyperprolactinemia and overall hypopituitarism caused by metastatic spread leading to the initial symptoms are rare. CASE SUMMARY: A 53-year-old male patient was admitted to our hospital with complaints of bilateral blurred vision, dizziness, polyuria, nocturia, severe fatigue and somnolence, decreased libido, and intermittent nausea and vomiting for more than 6 mo. During the last 7 d, the dizziness had worsened. Laboratory investigations revealed overall hypofunction of the pituitary gland, but the patient had an elevated serum prolactin level (703.35 mg/mL). Preoperative magnetic resonance imaging revealed a tumor in the sellar region, accompanied by intratumoral hemorrhage and calcification. Thus, transnasal subtotal resection of the lesion in the sellar region was performed. The histopathological and immunohistochemical examinations of the resected lesion revealed metastasis of lung adenocarcinoma to the pituitary gland. Oral hydrocortisone (30 mg/d) and levothyroxine (25 mg/d) were given both pre- and postoperatively. Post-operatively, the clinical symptoms were significantly improved. However, 4 mo following the surgery, the patient succumbed due to multiple organ failure. CONCLUSION: Hyperprolactinemia is one of the markers of poor prognosis in patients with carcinoma that metastasizes to the pituitary gland. Exogenous hormone supplementation plays a positive role in relieving the symptoms of patients and improving quality of life. |
format | Online Article Text |
id | pubmed-7809681 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-78096812021-01-27 Hyperprolactinemia due to pituitary metastasis: A case report Liu, Chun-Yang Wang, Yu-Bo Zhu, Hui-Qin You, Jin-Liang Liu, Zhuang Zhang, Xian-Feng World J Clin Cases Case Report BACKGROUND: Pituitary metastasis is an uncommon manifestation of systemic malignant tumors. Moreover, hyperprolactinemia and overall hypopituitarism caused by metastatic spread leading to the initial symptoms are rare. CASE SUMMARY: A 53-year-old male patient was admitted to our hospital with complaints of bilateral blurred vision, dizziness, polyuria, nocturia, severe fatigue and somnolence, decreased libido, and intermittent nausea and vomiting for more than 6 mo. During the last 7 d, the dizziness had worsened. Laboratory investigations revealed overall hypofunction of the pituitary gland, but the patient had an elevated serum prolactin level (703.35 mg/mL). Preoperative magnetic resonance imaging revealed a tumor in the sellar region, accompanied by intratumoral hemorrhage and calcification. Thus, transnasal subtotal resection of the lesion in the sellar region was performed. The histopathological and immunohistochemical examinations of the resected lesion revealed metastasis of lung adenocarcinoma to the pituitary gland. Oral hydrocortisone (30 mg/d) and levothyroxine (25 mg/d) were given both pre- and postoperatively. Post-operatively, the clinical symptoms were significantly improved. However, 4 mo following the surgery, the patient succumbed due to multiple organ failure. CONCLUSION: Hyperprolactinemia is one of the markers of poor prognosis in patients with carcinoma that metastasizes to the pituitary gland. Exogenous hormone supplementation plays a positive role in relieving the symptoms of patients and improving quality of life. Baishideng Publishing Group Inc 2021-01-06 2021-01-06 /pmc/articles/PMC7809681/ /pubmed/33511184 http://dx.doi.org/10.12998/wjcc.v9.i1.190 Text en ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Case Report Liu, Chun-Yang Wang, Yu-Bo Zhu, Hui-Qin You, Jin-Liang Liu, Zhuang Zhang, Xian-Feng Hyperprolactinemia due to pituitary metastasis: A case report |
title | Hyperprolactinemia due to pituitary metastasis: A case report |
title_full | Hyperprolactinemia due to pituitary metastasis: A case report |
title_fullStr | Hyperprolactinemia due to pituitary metastasis: A case report |
title_full_unstemmed | Hyperprolactinemia due to pituitary metastasis: A case report |
title_short | Hyperprolactinemia due to pituitary metastasis: A case report |
title_sort | hyperprolactinemia due to pituitary metastasis: a case report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7809681/ https://www.ncbi.nlm.nih.gov/pubmed/33511184 http://dx.doi.org/10.12998/wjcc.v9.i1.190 |
work_keys_str_mv | AT liuchunyang hyperprolactinemiaduetopituitarymetastasisacasereport AT wangyubo hyperprolactinemiaduetopituitarymetastasisacasereport AT zhuhuiqin hyperprolactinemiaduetopituitarymetastasisacasereport AT youjinliang hyperprolactinemiaduetopituitarymetastasisacasereport AT liuzhuang hyperprolactinemiaduetopituitarymetastasisacasereport AT zhangxianfeng hyperprolactinemiaduetopituitarymetastasisacasereport |